Literature DB >> 33420587

Jiaotai Pill () Alleviates Insomnia through Regulating Monoamine and Organic Cation Transporters in Rats.

Zhi-Hui Li1, Peng-Kai Ma1, Yun-Fang Huang, Zhe Zhang1, Wei Zheng1, Jian-Hua Chen1, Chang-E Guo1, Ning Chen1, Xin-Ning Bi1, Yu-Jie Zhang2.   

Abstract

OBJECTIVE: To reveal the effect and mechanism of Jiaotai Pill (, JTP) on insomniac rats.
METHODS: The insomniac model was established by intraperitoneal injection of p-chlorophenylalanine (PCPA). In behavioral experiments, rats were divided into control, insomniac model, JTP [3.3 g/(kg•d)], and diazepam [4 mg/(kg•d)] groups. The treatment effect of JTP was evaluated by weight measurement (increasement of body weight), open field test (number of crossings) and forced swimming test (immobility time). A high performance liquid chromatography-electrochemical detection (HPLC-ECD) method was built to determine the concentration of monoamine transmitters in hypothalamus and peripheral organs from normal, model, JTP, citalopram [30 mg/(kg•d)], maprotiline [40 mg/(kg•d)] and bupropion [40 mg/(kg•d)] groups. Expressions of serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET) were analyzed by quantitative polymerase chain reaction (qPCR) and Western blot in normal, model and JTP groups. A high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI-MS/MS) method was established to determine the pharmacokinetics, urine cumulative excretion of metformin in vivo, and tissue slice uptake in vitro, which were applied to assess the activity of organic cation transporters (OCTs) in hypothalamus and peripheral organs.
RESULTS: Compared with the insomniac model group, the body weight and spontaneous locomotor were increased, and the immobility time was decreased after treatment with JTP (P<0.01). Both serotonin and dopamine contents in hypothalamus and peripheral organs were increased (P<0.01). The norepinephrine content was increased in peripheral organs and decreased in hypothalamus (P<0.05 or P<0.01). At the same time, SERT, DAT, OCT1, OCT2, and OCT3 were down-regulated in hypothalamus and peripheral organs (P<0.05). NET was down-regulated in peripheral organs and up-regulated in hypothalamus (P<0.05 or P<0.01). Moreover, the activity of OCTs in hypothalamus and peripheral organs was inhibited (P<0.05).
CONCLUSION: JTP alleviates insomnia through regulation of monoaminergic system and OCTs in hypothalamus and peripheral organs.

Entities:  

Keywords:  Chinese medicine; Jiaotai Pill; hypothalamus; monoamine transmitters; monoaminergic system; peripheral organs; sleep disorder

Year:  2021        PMID: 33420587     DOI: 10.1007/s11655-021-3284-y

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  4 in total

1.  From Imaging the Brain to Imaging the Retina: Optical Coherence Tomography (OCT) in Schizophrenia.

Authors:  Carlos Schönfeldt-Lecuona; Thomas Kregel; Arno Schmidt; Elmar H Pinkhardt; Florian Lauda; Jan Kassubek; Bernhard J Connemann; Roland W Freudenmann; Maximilian Gahr
Journal:  Schizophr Bull       Date:  2015-06-05       Impact factor: 9.306

2.  Different relationships of spillover to release of norepinephrine in human heart, kidneys, and forearm.

Authors:  I J Kopin; B Rundqvist; P Friberg; J Lenders; D S Goldstein; G Eisenhofer
Journal:  Am J Physiol       Date:  1998-07

3.  Muramyl dipeptide and IL-1 effects on sleep and brain temperature after inhibition of serotonin synthesis.

Authors:  L Imeri; S Bianchi; M Mancia
Journal:  Am J Physiol       Date:  1997-11

Review 4.  The neuroendocrine system: organization and homeostatic role.

Authors:  R Toni
Journal:  J Endocrinol Invest       Date:  2004       Impact factor: 4.256

  4 in total
  1 in total

Review 1.  Traditional East Asian Herbal Medicine for Post-Stroke Insomnia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Sang-Ho Kim; Jung-Hwa Lim
Journal:  Int J Environ Res Public Health       Date:  2022-02-03       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.